Fetal Neuroprotection Clinical Trial
Official title:
Effect of Magnesium Sulfate for Fetal Neuroprotection on Fetal Heart Rate in Case of Prematurity
Type of study: prospective descriptive monocentric study
Population: 2 groups: -Exposed group: pregnant patient between 24AW+0day and 32AW+0day
receiving magnesium sulfate for fetal neuroprotection in the doubt of premature delivery
- Control group: pregnant patient between 32AW+1day and 35AW+0day in the same context not
requiring magnesium sulfate due to their gestationnal age.
Criterion(s) of judgment: Appearance of a change in short-term variability after injection of
magnesium sulfate in the exposed group compared to the control group.
Schedule: Inclusion from February 20 to August 31, 2018
Expected results and prospects:
The general impression during my semester at the Jeanne de Flandre maternity clinic in Lille
was the variability improves after injection of the magnesium sulfate used in the premature
infant as a neuroprotective. The investigators would like to proove that the use of magnesium
sulfate as neuroprotective in premature fetuses would improve the fetal heart rate by
increasing variability.
In the literature there are numerous publications on the effects of magnesium sulfate used as
tocolytic (higher doses) in the threats of premature labour, generally showing a variability
and number accelerations decreases without increase the number of decelerations. Is this
effect is the same as the doses used for fetal neuroprotection?
Expected benefits of the research:
Magnesium sulfate used on premature infants for fetal neuroprotection has an impact on fetal
heart rate, including variability and number of accelerations.
Investigation plan:
Exposed group: fetuses aged 24 + 0AW to 32 + 0AW and benefiting from MgSO4 for
neuroprotective purposes, with decision of extraction or spontaneous labour or induced
labour:
1 FHR + STV before MgSO4 bolus
1. FHR + STV 10 minutes after the start of the MgSO4 bolus
Control group: fetuses aged 32 + 1SA to 35 + 0SA without MgSO4, with extraction decision
or spontaneous labour or induced labour:
2. FHR + STV at 10 minutes interval : 1 STV at the entrance if suspicion premature labour
(in the delivery room) then another 10 minutes after; 2 STV at 10 minutes interval if
extraction decision.
Statistical Analysis Plan:
Measurement of the STV value difference before / after MgSO4 in the exposed group and the STV
value difference between the 2 measurements in the control group and comparison of these
differences.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04401852 -
Magnesium Sulfate for Fetal Neuroprotection
|
N/A | |
| Completed |
NCT02133573 -
Randomized Trial of Maternal Progesterone Therapy
|
Phase 2 |